Journal
CANCERS
Volume 12, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/cancers12020455
Keywords
multiple myeloma; KRAS; MEK/ERK-signaling; AKT-signaling; amplicon sequencing
Categories
Funding
- Deutsche Krebshilfe [70112693]
- Wilhelm Sander-Stiftung [2014.903.1]
- Deutsche Forschungsgemeinschaft [KFO 216]
- Open Access Publication Fund of the University of Wurzburg
Ask authors/readers for more resources
Approximately 20% of multiple myeloma (MM) cases harbor a point mutation in KRAS. However, there is still no final consent on whether KRAS-mutations are associated with disease outcome. Specifically, no data exist on whether KRAS-mutations have an impact on survival of MM patients at diagnosis in the era of novel agents. Direct blockade of KRAS for therapeutic purposes is mostly impossible, but recently a mutation-specific covalent inhibitor targeting KRAS(p.G12C) entered into clinical trials. However, other KRAS hotspot-mutations exist in MM patients, including the less common exon-4 mutations. For the current study, the coding regions of KRAS were deep-sequenced in 80 newly diagnosed MM patients, uniformely treated with three cycles of bortezomib plus dexamethasone and cyclophosphamide (VCD)-induction, followed by high-dose chemotherapy and autologous stem cell transplantation. Moreover, the functional impact of KRAS(p.G12A) and the exon-4 mutations p.A146T and p.A146V on different survival pathways was investigated. Specifically, KRAS(WT), KRAS(p.G12A), KRAS(p.A146T), and KRAS(p.A146V) were overexpressed in HEK293 cells and the KRAS(WT) MM cell lines JJN3 and OPM2 using lentiviral transduction and the Sleeping Beauty vector system. Even though KRAS-mutations were not correlated with survival, all KRAS-mutants were found capable of potentially activating MEK/ERK- and sustaining PI3K/AKT-signaling in MM cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available